The global D-Dimer market is anticipated to grow significantly over the forecast period. D-dimer is a protein fragment, which has two cross-linked D fragment of a protein called fibrin. It is a fibrin degradation product (FDP) which is found in human blood samples after the blood clot is degraded by fibrinolysis. They are present in blood plasma only when the blood coagulation system has been activated due to the presence of disseminated intravascular coagulation or thrombosis. D-dimers are responsible for the activation of the hemostatic system. Driving factors for the growth of this market are increasing the occurrence of various pulmonary and cardiovascular diseases which can cause various life-threatening issues due to blood clot formation in the pulmonary and arterial pathway. Increasing incidence of pulmonary embolisms and heart strokes and rising demand for advanced coagulation testing techniques which brings more revenues to this market. It examines overall market applications of monoclonal antibodies, chromogenic substrates, DNA probes, immunoassays, biochips/microarrays, IT, and other technologies.
On the basis of disease diagnoses, the D-dimer market can be classified into three major segments namely deep venous thrombosis (DVT), pulmonary embolism (PE), and venous thromboembolism (VTE). Standardized D-Dimer is expected to offer opportunities for quality control products, services, and is highly useful in the setting of an emergency department. There are different D-dimer assays qualitative and quantitative and both tests are highly sensitive and show predictive values. The level of D-dimer is higher in non-pathological conditions such as pregnancy, age especially in geriatric, cigarette smoking, race, post-operatively, functional impairment, genetic factors and in pathological conditions such as acute coronary syndromes, aortic dissection, acute upper gastrointestinal hemorrhage, atrial fibrillation, arterial or venous thromboembolism, infection, consumptive coagulopathy such as VICC and DIC, pre-eclampsia, malignancy, stroke, sickle cell disease, trauma, and superficial thrombophlebitis.
The D-dimer market is segmented into four major regions such as Europe, North America, Asia- Pacific, and RoW. North American market dominates the global market followed by Europe market due to increasing technology and rising clinical trial studies and medical practices. Asia-Pacific region shows the fastest growth rate due to rising incidence rates of cardiovascular diseases due to changing lifestyles and habits, increasing competition. Some of the key players operating in this market include Abbott Laboratories, Inc., Becton, Bio/Data Corporation, Beckman Coulter Inc., Dickinson & Company, Corgenix, F. Nanogen, Hoffmann-La Roche Ltd., Siemens Healthcare, Trinity Biotech plc., Thermo & Fischer Scientific, Inc.
This report by Grand View Research provides complete market estimates and forecasts up to 2020. The study also explains in detail various market dynamics including key drivers, restraints, growth opportunities, and competitive landscape.
Key questions answered by the report include:
1. What is the current market size and what are the future growth prospects of the market
2. What are the key applications in the market and what is their future potential
3. What are the factors driving market growth and what are the key challenges for participants in this industry
4. How will key regional markets perform up to 2020
5. What is the competitive scenario in the market, which companies are expected to lead the market over the next six years
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.